Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 3.06B | 2.85B | 2.42B | 2.10B | 1.85B | 1.86B |
Gross Profit | 2.44B | 2.27B | 1.89B | 1.59B | 1.38B | 1.34B |
EBITDA | 895.24M | 650.86M | 310.28M | 267.51M | 48.03M | 13.41M |
Net Income | 657.24M | 426.86M | 167.65M | 141.56M | -64.08M | 854.03M |
Balance Sheet | ||||||
Total Assets | 7.46B | 6.99B | 6.84B | 6.38B | 6.00B | 5.85B |
Cash, Cash Equivalents and Short-Term Investments | 1.43B | 1.14B | 1.07B | 1.29B | 1.01B | 1.07B |
Total Debt | 603.87M | 602.71M | 1.10B | 1.09B | 1.09B | 1.09B |
Total Liabilities | 1.43B | 1.33B | 1.89B | 1.77B | 1.74B | 1.74B |
Stockholders Equity | 6.03B | 5.66B | 4.95B | 4.60B | 4.27B | 4.11B |
Cash Flow | ||||||
Free Cash Flow | 691.43M | 475.42M | 51.65M | 44.36M | 185.31M | -52.15M |
Operating Cash Flow | 766.77M | 572.84M | 159.26M | 175.90M | 304.54M | 85.36M |
Investing Cash Flow | 19.42M | 136.49M | -111.24M | -20.03M | -366.31M | -53.62M |
Financing Cash Flow | -539.65M | -526.45M | -18.73M | -18.65M | -48.00K | 181.12M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $15.30B | 12.32 | 26.08% | ― | 23.25% | 64.46% | |
80 Outperform | $16.52B | 19.23 | 24.30% | ― | 18.87% | 1088.27% | |
78 Outperform | $13.78B | 11.90 | 19.30% | ― | 17.62% | 19.89% | |
77 Outperform | $11.19B | 17.26 | 11.62% | ― | 17.38% | 153.58% | |
75 Outperform | $10.07B | 17.95 | 29.00% | ― | 10.73% | 81.66% | |
61 Neutral | $11.76B | ― | 357.68% | ― | 55.77% | 46.81% | |
51 Neutral | $7.86B | -0.26 | -41.41% | 2.22% | 22.87% | -2.01% |
On August 5, 2025, BioMarin Pharmaceutical announced the resignation of Erin Burkhart, their Group Vice President and Chief Accounting Officer, effective September 2, 2025. The company will search for her successor, and in the interim, Brian Mueller, the Executive Vice President and Chief Financial Officer, will assume her responsibilities without additional compensation.
On July 30, 2025, BioMarin Pharmaceutical‘s Board of Directors expanded from ten to eleven members, appointing Ian T. Clark effective August 1, 2025. Mr. Clark joins the Audit and Science and Technology Committees, receiving standard director fees and a $400,000 restricted stock unit grant. This strategic move aims to strengthen BioMarin’s governance and oversight, potentially enhancing its industry positioning and stakeholder confidence.